{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2023_00028715", "CSN": null, "TRF": "ORD_1611555_01", "MRN": "49390887", "PhysicianId": "109266", "NPI": null}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1308905", "clinicalId": "1310255", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1611555_01", "SampleName": "US1538289.01", "Version": "0", "Sample": {"FM_Id": "ORD_1611555_01", "SampleId": "US1538289.01", "BlockId": "S112-66474N", "TRFNumber": "ORD_1611555_01", "TestType": "FoundationOne Heme", "SpecFormat": "FFPE", "ReceivedDate": "2023_04_17", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "7010 Kit Creek Road, Morrisville, NC 27560", "cliaNumber": "34D2044309", "locationID": "2", "locationName": "RTP", "processID": "2", "processName": "Extracted DNA"}]}, "TumorPurity": "40", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "M112-10092", "MRN": "49390887", "FullName": "\u738b\u99a5\u5a77", "FirstName": "Fu Ting", "LastName": "Wang", "SubmittedDiagnosis": "perivascular epithelioid cell tumor (PEComa)", "Gender": "Female", "DOB": "1996_04_18", "OrderingMD": "\u738b\u9d6c\u60e0", "OrderingMDId": "109266", "Pathologist": "\u6797\u58eb\u582f", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Vagina", "CollDate": "2023_04_07", "ReceivedDate": "2023-05-03 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Sarcoma"}, "PertinentNegatives": null, "Summaries": {"alterationCount": "10", "clinicalTrialCount": "10", "resistiveCount": "0", "sensitizingCount": "1"}, "VariantProperties": {"VariantProperty": [{"geneName": "APC", "isVUS": "true", "variantName": "V1125A"}, {"geneName": "ASXL1", "isVUS": "true", "variantName": "N114K"}, {"geneName": "FLT1", "isVUS": "true", "variantName": "R812W"}, {"geneName": "MAP3K14", "isVUS": "true", "variantName": "R99C"}, {"geneName": "NUP98", "isVUS": "true", "variantName": "K1631Q"}, {"geneName": "PRKDC", "isVUS": "true", "variantName": "R3282S"}, {"geneName": "SOCS1", "isVUS": "true", "variantName": "T15I"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "TFE3", "Include": "true", "Alterations": {"Alteration": {"Name": "NONO_TFE3 fusion", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "NONO_TFE3 fusion"}}, "Interpretation": "TFE3 encodes the transcription factor for immunoglobulin heavy chain enhancer 3 protein. Multiple fusions with TFE3 as a 3\u2019 partner have been reported in cancer and characterized as activating (Gotoh et al., 2014; 25230976, Kobos et al., 2013; 23288701, Argani et al., 2001; 11438465, Clark et al., 1997; 9393982, Weterman et al., 2000; 10644981, Skalsky et al., 2001; 11313942). NONO_TFE3 fusions have been reported in renal cell carcinomas (Clark et al., 1997; 9393982, Sato et al., 2013; 23797736, Xia et al., 2016; 27934879, Argani et al., 2016; 26975036) and neoplasms with melanocytic differentiation including melanocytic perivascular epithelioid cell neoplasms (PEComas)(Argani et al., 2016; 26975036, McGregor et al., 2017; 28009605, Wang et al., 2016; 26844676) and are likely activating (Davis et al., 2006; 16766266, Sato et al., 2013; 23797736, Kauffman et al., 2014; 25048860), although one in vitro study found NONO_TFE3 was unable to activate transcription (Skalsky et al., 2001; 11313942). TFE3 rearrangements have been observed in a variety of types of perivascular epithelioid cell tumors (PEComa), including those of cervical, renal, and uterine origin (Liu et al., 2014; 25337301, Argani et al., 2010; 20871214, Schoolmeester et al., 2015; 25517951). Due to the low frequency of PEComa cases, the incidence of TFE3 rearrangement or mutation in PEComa is unclear. However, one study tested 29 PEComa patients for TFE3 alteration and identified 4 (14%) patients with TFE3 rearrangements and concomitant increased TFE3 expression as well as an additional 4 (14%) patients with increased TFE3 expression (Argani et al., 2010; 20871214). Another study reported TFE3 rearrangement in 23% (9/38) of PEComa patients and identified TFE3 rearrangements as being mutually exclusive from TSC2 mutation, a frequent mutation found in PEComa (Agaram et al., 2015; 25651471). TFE3 rearrangements are generally rare in human cancer but characterize Xp11 translocation cancers, which include renal cell carcinoma, perivascular epithelioid cell tumor (PEComa), epithelioid hemangioendothelioma, alveolar soft part sarcoma, and melanotic Xp11 neoplasm, with a variety of TFE3 fusion partners reported in these diseases (Wang et al., 2018; 29713041). An analysis of 3 PEComa patients with TFE3 rearrangement and increased expression reported that 2 of the 3 patients exhibited histological malignancy and aggressive growth, while the other patient exhibited a benign course (Shen et al., 2014; 25239799). Clinical benefit in certain TFE3_rearranged solid tumors has been reported in response to anti_angiogenic agents such as sunitinib (Choueiri et al., 2010; 20665500, Malouf et al., 2010; 20154303, Numakura et al., 2011; 21161315, Liu et al., 2011; 21965162, Chowdhury et al., 2013; 22995920, Stacchiotti et al., 2009; 19188185, Stacchiotti et al., 2011; 21242589, Orbach et al., 2013; 23857870), sorafenib (Choueiri et al., 2010; 20665500, Malouf et al., 2010; 20154303), and cediranib (Kummar et al., 2013; 23630200, Judson et al., 2014; 24714778); to mTOR inhibitors (Marcon et al., 2020; 32220885, Qu et al., 2016; 27026382, Rua Fernandez et al., 2018; 29702156, Koh et al., 2013; 23180114, Kakoki et al., 2017; 28190703, Malouf et al., 2010; 20154303, Parikh et al., 2009; 21139932); and to MET inhibitors (Schoffski et al., 2017; 29216400, Wedekind et al., 2017; 28417541). Clinical studies have shown high response rates to treatment with sunitinib for patients with TFE3 fusion_associated cancers, including alveolar soft part sarcoma (ASPS) (Stacchiotti et al., 2009; 19188185, Stacchiotti et al., 2011; 21242589, Orbach et al., 2013; 23857870) and translocation renal cell carcinoma (tRCC or Xp11.2 RCC) (Choueiri et al., 2010; 20665500, Malouf et al., 2010; 20154303, Numakura et al., 2011; 21161315, Liu et al., 2011; 21965162, Chowdhury et al., 2013; 22995920). In addition, TFE3 fusions result in increased MET expression (Tsuda et al., 2007; 17283122, Kobos et al., 2013; 23288701, Schoffski et al., 2017; 29216400) and clinical and preclinical sensitivity to MET inhibitors (Schoffski et al., 2017; 29216400, Tsuda et al., 2007; 17283122, Wedekind et al., 2017; 28417541); a Phase 2 study of crizotinib to treat advanced or metastatic ASPS reported 1 PR and 35 SDs out of 40 MET_expressing cases (Schoffski et al., 2017; 29216400). Two patients with Xp11.2 RCC experienced clinical benefit from immune checkpoint inhibitors, with ongoing time on treatments of 37 and 15.7 months in a retrospective analysis (n=8) (Marcon et al., 2020; 32220885). TFE3 rearrangements are characteristic of a group of neoplasms known as Xp11 translocation cancers, which include renal cell carcinoma, PEComa, epithelioid hemangioendothelioma, alveolar soft part sarcoma, and melanotic Xp11 neoplasm (Wang et al., 2018; 29713041, Weterman et al., 1996; 8986805, Argani et al., 2003; 12917640, Bruder et al., 2004; 15316311, Trpkov et al., 2021; 33664427, Moch et al., 2016; 26935559, Argani et al., 2006; 6575003, Cajaiba et al., 2018; 29905933).", "Include": "true", "ClinicalTrialNote": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Therapies": {"Therapy": {"Name": null, "GenericName": "Sunitinib", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Sunitinib is a small_molecule tyrosine kinase inhibitor that targets PDGFRs, VEGFRs, KIT, FLT3, CSF_1R, and RET. It is FDA approved for the treatment of advanced or metastatic pancreatic neuroendocrine tumors, gastrointestinal stromal tumors (GISTs) in patients who have progressed on or are intolerant to imatinib, and advanced renal cell carcinoma (RCC) as well as for the adjuvant treatment of patients at high risk of recurrent RCC after nephrectomy. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> TFE3 fusions may confer sensitivity to sunitinib, based on both clinical (Stacchiotti et al., 2009; 19188185, Stacchiotti et al., 2011; 21242589, Orbach et al., 2013; 23857870, Choueiri et al., 2010; 20665500, Malouf et al., 2010; 20154303, Numakura et al., 2011; 21161315, Liu et al., 2011; 21965162, Chowdhury et al., 2013; 22995920) and preclinical (Vistica et al., 2009; 19636271, Covell et al., 2012; 23226201, Kobos et al., 2013; 23288701, Ford and D Amore, 2012; 22419845) evidence. </p> <p><b>Supporting Data:</b> Clinical data on the efficacy of sunitinib for the treatment of PEComa and angiomyolipoma are limited (PubMed, Apr 2023). A patient with malignant PEComa of the kidney treated with sunitinib for 4 weeks followed by resection exhibited a durable response before progressing (AlAzab et al., 2019; 32010646). A patient with epithelioid angiomyolipoma (EAML) of kidney treated with sunitinib had a short response for 2 months (Citak et al., 2015; 26279736). Another patient with kidney EAML who was treated with sunitinib for a short time and then switched to everolimus experienced favorable response for 30 months (Hulova et al., 2018; 30545225). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT03175224", "Include": "true"}, {"nctId": "NCT05439993", "Include": "true"}, {"nctId": "NCT03784014", "Include": "true"}, {"nctId": "NCT04817956", "Include": "true"}, {"nctId": "NCT04220229", "Include": "true"}, {"nctId": "NCT04200443", "Include": "true"}, {"nctId": "NCT05135975", "Include": "true"}, {"nctId": "NCT05468359", "Include": "true"}, {"nctId": "NCT02484404", "Include": "true"}, {"nctId": "NCT05038839", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). In a computational analysis of paired tumor and normal sarcomas in the TCGA dataset, of which 25% were liposarcomas, only 0.8% (2/255) of samples were MSI_high (MSI_H) (Bonneville et al., 2017; 29850653). However, reports of MSI in sarcomas in the literature are conflicting and varied due to substantial heterogeneity, lack of consensus on the markers and methods used for MSI assessment, and small sample size in most studies (Monument et al., 2012; 23401795). In these smaller studies of soft tissue sarcoma, reports of MSI at any level have been rare, with the highest incidences between 11% (2/18) to 25% (10/40) of cases (Wooster al., 1994; 8162069, Kawaguchi et al., 2005; 15643505, Saito et al., 2003; 14562278, Suwa et al., 1999; 10370164, Garcia et al., 2006; 16619000, Aue et al., 1998; 9689926). In one study, MSI was reported to occur more frequently in high_grade soft tissue sarcomas compared with lower grade (Ruci\u0144ska et al., 2005; 15668629). However, published data investigating the prognostic implications of MSI in sarcoma are limited (PubMed, Jan 2023). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "00", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "00"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD_1_ or PD_L1_targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types (Goodman et al., 2017; 28835386, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947). Perivascular epithelioid cell tumors harbor a median TMB of 1.6 mutations per megabase (muts/Mb) in a study of 31 cases (Akumalla et al., 2020; 32966992). Soft tissue sarcomas harbor a median tumor mutational burden (TMB) of 2.4_2.5 mutations per megabase (muts/Mb), with angiosarcoma (up to 15%) and malignant peripheral nerve sheath tumor (up to 11%) having the highest percentage of cases with high TMB (Gounder et al., 2022; 35705558, FMI_Chalmers et al., 2017; 28420421). In a study, 3.9% of soft tissue sarcoma samples analyzed harbor TMB \u226510 muts/Mb (Gounder et al., 2022; 35705558); in addition, increased mutational burden has been reported in undifferentiated pleomorphic sarcomas as compared with Ewing sarcomas or rhabdomyosarcomas (Lim et al., 2015; 26330427, Brohl et al., 2014; 25010205, Chen et al., 2013; 24332040). Published data investigating the prognostic implications of tissue TMB in sarcoma are conflicting (PubMed, Feb 2023). High tissue TMB was associated with improved PFS and metastasis_free survival in a study of undifferentiated sarcomas (Steele et al., 2019; 30889380), but with reduced survival in a study of patients with rhabdomyosarcoma (Casey et al., 2020; 31699828). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In multiple pan_tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors (Legrand et al., 2018; ASCO Abstract 12000, Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2020; 32919526, Goodman et al., 2019; 31405947, Ott et al., 2019; 30557521, Cristescu et al., 2022; 35101941, Friedman et al., 2022; 34876409, Sturgill et al., 2022; 35274716). In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB \u226510 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types (Marabelle et al., 2020; 32919526); similar findings were observed in the KEYNOTE 028 and 012 trials (Cristescu et al., 2018; 30309915). At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores \u2265 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68) (Sturgill et al., 2022; 35274716). For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB \u2265 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples (Schenker at al., 2022; AACR Abstract 7845). However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan_solid tumors, where improved ORR and DCR was seen in patients with TMB \u2265 16 Muts/Mb than those with TMB \u2265 10 and <16 Muts/Mb (Friedman et al., 2022; 34876409). Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as \u226516_20 Muts/Mb) achieved greater clinical benefit from PD_1 or PD_L1_targeting monotherapy compared with patients with higher TMB treated with chemotherapy (Legrand et al., 2018; ASCO Abstract 12000) or those with lower TMB treated with PD_1 or PD_L1_targeting agents (Goodman et al., 2017; 28835386).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "CBT_101 Study for Advanced Solid Tumors and c_Met Dysregulation", "StudyPhase": "PHASE 1/2", "Target": "MET", "Locations": "Taipei City (Taiwan), Taipei (Taiwan), New Taipei City (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Tainan (Taiwan), Singapore (Singapore), Nedlands (Australia), North Adelaide (Australia), Bedford Park (Australia)", "NCTID": "NCT03175224", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma", "StudyPhase": "PHASE 1/2", "Target": "MET", "Locations": "Gyeonggi_do (Korea, Republic of)", "NCTID": "NCT05439993", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "MOLECULAR PROFILING OF ADVANCED SOFT_TISSUE SARCOMAS", "StudyPhase": "PHASE 3", "Target": "ABL, KIT, ROS1, ALK, MET, ERBB2, EGFR, BRAF, MEK, PARP, PD_L1, CDK4, CDK6", "Locations": "Strasbourg (France), Dijon (France), Paris (France), Villejuif (France), Lyon (France), Clermont_Ferrand (France), Marseille (France), Saint_Herblain (France), Bordeaux (France)", "NCTID": "NCT03784014", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Improving Public Cancer Care by Implementing Precision Medicine in Norway", "StudyPhase": "PHASE 2", "Target": "PD_L1, VEGFA, ERBB2, ALK, RET, PARP, SMO, TRKB, TRKC, ROS1, TRKA, MEK, BRAF, PI3K_alpha, FGFR1, FGFR2, FGFR3, MET, KIT, ABL", "Locations": "Troms\u00f8 (Norway), Bod\u00f8 (Norway), Hamar (Norway), Oslo (Norway), Fredrikstad (Norway), Drammen (Norway), Trondheim (Norway), Skien (Norway), F\u00f8rde (Norway), Bergen (Norway)", "NCTID": "NCT04817956", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities", "StudyPhase": "PHASE 1/2", "Target": "MET, ROS1, RET, VEGFRs", "Locations": "Washington", "NCTID": "NCT04220229", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma", "StudyPhase": "PHASE 2", "Target": "MET, ROS1, RET, VEGFRs", "Locations": "California, Iowa, Wisconsin, Illinois, Missouri", "NCTID": "NCT04200443", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High_Risk Pediatric Solid Tumors", "StudyPhase": "PHASE 2", "Target": "MET, ROS1, RET, VEGFRs", "Locations": "Ohio", "NCTID": "NCT05135975", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients", "StudyPhase": "PHASE 1/2", "Target": "RET, KIT, RAFs, FLT3, VEGFRs, VEGFA, PD_L1", "Locations": "Tennessee", "NCTID": "NCT05468359", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Phase I/II Study of the Anti_Programmed Death Ligand_1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers", "StudyPhase": "PHASE 1/2", "Target": "PARP, VEGFRs, PDGFRA, PDGFRB, KIT, PD_L1", "Locations": "Maryland", "NCTID": "NCT02484404", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}, {"Gene": "TFE3", "Alteration": "NONO_TFE3 fusion", "Title": "Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors", "StudyPhase": "PHASE 1", "Target": "MET, ROS1, RET, VEGFRs, PARP", "Locations": "Texas", "NCTID": "NCT05038839", "Note": "TFE3 fusions may activate angiogenic pathways and increase expression of the MET oncogene and may therefore confer sensitivity to MET inhibitors or to tyrosine kinase inhibitors such as sunitinib, sorafenib, or cediranib. TFE3 fusions may also predict sensitivity to mTOR inhibitors.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "25230976", "FullCitation": "Gotoh M, et al. Genes Chromosomes Cancer (2014) pmid: 25230976", "Include": "true"}, {"number": "1", "ReferenceId": "23288701", "FullCitation": "Kobos R, et al. J. Pathol. (2013) pmid: 23288701", "Include": "true"}, {"number": "2", "ReferenceId": "11438465", "FullCitation": "Argani P, et al. Am. J. Pathol. (2001) pmid: 11438465", "Include": "true"}, {"number": "3", "ReferenceId": "9393982", "FullCitation": "Clark J, et al. Oncogene (1997) pmid: 9393982", "Include": "true"}, {"number": "4", "ReferenceId": "10644981", "FullCitation": "Weterman MJ, et al. Oncogene (2000) pmid: 10644981", "Include": "true"}, {"number": "5", "ReferenceId": "11313942", "FullCitation": "Skalsky YM, et al. Oncogene (2001) pmid: 11313942", "Include": "true"}, {"number": "6", "ReferenceId": "23797736", "FullCitation": "Sato Y, et al. Nat. Genet. (2013) pmid: 23797736", "Include": "true"}, {"number": "7", "ReferenceId": "27934879", "FullCitation": "Xia QY, et al. Mod Pathol (2017) pmid: 27934879", "Include": "true"}, {"number": "8", "ReferenceId": "26975036", "FullCitation": "Argani P, et al. Am. J. Surg. Pathol. (2016) pmid: 26975036", "Include": "true"}, {"number": "9", "ReferenceId": "28009605", "FullCitation": "McGregor SM, et al. Am J Surg Pathol (2017) pmid: 28009605", "Include": "true"}, {"number": "10", "ReferenceId": "26844676", "FullCitation": "Wang XT, et al. Histopathology (2016) pmid: 26844676", "Include": "true"}, {"number": "11", "ReferenceId": "16766266", "FullCitation": "Davis IJ, et al. Cancer Cell (2006) pmid: 16766266", "Include": "true"}, {"number": "12", "ReferenceId": "25048860", "FullCitation": "Kauffman EC, et al. Nat Rev Urol (2014) pmid: 25048860", "Include": "true"}, {"number": "13", "ReferenceId": "25337301", "FullCitation": "Liu F, et al. Int J Clin Exp Pathol (2014) pmid: 25337301", "Include": "true"}, {"number": "14", "ReferenceId": "20871214", "FullCitation": "Argani P, et al. Am. J. Surg. Pathol. (2010) pmid: 20871214", "Include": "true"}, {"number": "15", "ReferenceId": "25517951", "FullCitation": "Schoolmeester JK, et al. Am. J. Surg. Pathol. (2015) pmid: 25517951", "Include": "true"}, {"number": "16", "ReferenceId": "25651471", "FullCitation": "Agaram NP, et al. Am. J. Surg. Pathol. (2015) pmid: 25651471", "Include": "true"}, {"number": "17", "ReferenceId": "29713041", "FullCitation": "Wang XT, et al. Mod. Pathol. (2018) pmid: 29713041", "Include": "true"}, {"number": "18", "ReferenceId": "25239799", "FullCitation": "Shen Q, et al. Virchows Arch. (2014) pmid: 25239799", "Include": "true"}, {"number": "19", "ReferenceId": "20665500", "FullCitation": "Choueiri TK, et al. Cancer (2010) pmid: 20665500", "Include": "true"}, {"number": "20", "ReferenceId": "20154303", "FullCitation": "Malouf GG, et al. Ann. Oncol. (2010) pmid: 20154303", "Include": "true"}, {"number": "21", "ReferenceId": "21161315", "FullCitation": "Numakura K, et al. Int. J. Clin. Oncol. (2011) pmid: 21161315", "Include": "true"}, {"number": "22", "ReferenceId": "21965162", "FullCitation": "Liu YC, et al. Jpn. J. Clin. Oncol. (2011) pmid: 21965162", "Include": "true"}, {"number": "23", "ReferenceId": "22995920", "FullCitation": "Chowdhury T, et al. J. Pediatr. Hematol. Oncol. (2013) pmid: 22995920", "Include": "true"}, {"number": "24", "ReferenceId": "19188185", "FullCitation": "Stacchiotti S, et al. Clin. Cancer Res. (2009) pmid: 19188185", "Include": "true"}, {"number": "25", "ReferenceId": "21242589", "FullCitation": "Stacchiotti S, et al. Ann. Oncol. (2011) pmid: 21242589", "Include": "true"}, {"number": "26", "ReferenceId": "23857870", "FullCitation": "Orbach D, et al. Pediatr Blood Cancer (2013) pmid: 23857870", "Include": "true"}, {"number": "27", "ReferenceId": "23630200", "FullCitation": "Kummar S, et al. J. Clin. Oncol. (2013) pmid: 23630200", "Include": "true"}, {"number": "28", "ReferenceId": "24714778", "FullCitation": "Judson I, et al. Clin. Cancer Res. (2014) pmid: 24714778", "Include": "true"}, {"number": "29", "ReferenceId": "32220885", "FullCitation": "Marcon J, et al. Clin Cancer Res (2020) pmid: 32220885", "Include": "true"}, {"number": "30", "ReferenceId": "27026382", "FullCitation": "Qu Y, et al. Sci Rep (2016) pmid: 27026382", "Include": "true"}, {"number": "31", "ReferenceId": "29702156", "FullCitation": "Rua Fern\u00e1ndez OR, et al. Urology (2018) pmid: 29702156", "Include": "true"}, {"number": "32", "ReferenceId": "23180114", "FullCitation": "Koh Y, et al. Ann Oncol (2013) pmid: 23180114", "Include": "true"}, {"number": "33", "ReferenceId": "28190703", "FullCitation": "Kakoki K, et al. Clin Genitourin Cancer (2017) pmid: 28190703", "Include": "true"}, {"number": "34", "ReferenceId": "21139932", "FullCitation": "Parikh J, et al. Rare Tumors (2009) pmid: 21139932", "Include": "true"}, {"number": "35", "ReferenceId": "29216400", "FullCitation": "Sch\u00f6ffski P, et al. Ann. Oncol. (2018) pmid: 29216400", "Include": "true"}, {"number": "36", "ReferenceId": "28417541", "FullCitation": "Wedekind MF, et al. Pediatr Blood Cancer (2017) pmid: 28417541", "Include": "true"}, {"number": "37", "ReferenceId": "17283122", "FullCitation": "Tsuda M, et al. Cancer Res. (2007) pmid: 17283122", "Include": "true"}, {"number": "38", "ReferenceId": "8986805", "FullCitation": "Weterman MA, et al. Proc Natl Acad Sci U S A (1996) pmid: 8986805", "Include": "true"}, {"number": "39", "ReferenceId": "12917640", "FullCitation": "Argani P, et al. Oncogene (2003) pmid: 12917640", "Include": "true"}, {"number": "40", "ReferenceId": "15316311", "FullCitation": "Bruder E, et al. Am. J. Surg. Pathol. (2004) pmid: 15316311", "Include": "true"}, {"number": "41", "ReferenceId": "33664427", "FullCitation": "Trpkov K, et al. Mod Pathol (2021) pmid: 33664427", "Include": "true"}, {"number": "42", "ReferenceId": "26935559", "FullCitation": "Moch H, et al. Eur Urol (2016) pmid: 26935559", "Include": "true"}, {"number": "43", "ReferenceId": "6575003", "FullCitation": "Warren TE, et al. Heart Lung (1983) pmid: 6575003", "Include": "true"}, {"number": "44", "ReferenceId": "29905933", "FullCitation": "Cajaiba MM, et al. Cancer (2018) pmid: 29905933", "Include": "true"}, {"number": "45", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "46", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "47", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "48", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "49", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "50", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "51", "ReferenceId": "29850653", "FullCitation": "Bonneville R, et al. JCO Precis Oncol (2017) pmid: 29850653", "Include": "true"}, {"number": "52", "ReferenceId": "23401795", "FullCitation": "Monument MJ, et al. ISRN Oncol (2012) pmid: 23401795", "Include": "true"}, {"number": "53", "ReferenceId": "8162069", "FullCitation": "Wooster R, et al. Nat. Genet. (1994) pmid: 8162069", "Include": "true"}, {"number": "54", "ReferenceId": "15643505", "FullCitation": "Kawaguchi K, et al. Oncol. Rep. (2005) pmid: 15643505", "Include": "true"}, {"number": "55", "ReferenceId": "14562278", "FullCitation": "Saito T, et al. Hum. Pathol. (2003) pmid: 14562278", "Include": "true"}, {"number": "56", "ReferenceId": "10370164", "FullCitation": "Suwa K, et al. J Orthop Sci (1999) pmid: 10370164", "Include": "true"}, {"number": "57", "ReferenceId": "16619000", "FullCitation": "Garcia JJ, et al. Mod. Pathol. (2006) pmid: 16619000", "Include": "true"}, {"number": "58", "ReferenceId": "9689926", "FullCitation": "Aue G, et al. Cancer Genet. Cytogenet. (1998) pmid: 9689926", "Include": "true"}, {"number": "59", "ReferenceId": "15668629", "FullCitation": "Ruci\u0144ska M, et al. Med. Sci. Monit. (2005) pmid: 15668629", "Include": "true"}, {"number": "60", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "61", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "62", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "63", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "64", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "65", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "66", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "67", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "68", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "69", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "70", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "71", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "72", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "73", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "74", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "75", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "76", "ReferenceId": "32919526", "FullCitation": "Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526", "Include": "true"}, {"number": "77", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "78", "ReferenceId": "32966992", "FullCitation": "Akumalla S, et al. Oncology (2020) pmid: 32966992", "Include": "true"}, {"number": "79", "ReferenceId": "35705558", "FullCitation": "Gounder MM, et al. Nat Commun (2022) pmid: 35705558", "Include": "true"}, {"number": "80", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "81", "ReferenceId": "26330427", "FullCitation": "Lim J, et al. Clin. Cancer Res. (2015) pmid: 26330427", "Include": "true"}, {"number": "82", "ReferenceId": "25010205", "FullCitation": "Brohl AS, et al. PLoS Genet. (2014) pmid: 25010205", "Include": "true"}, {"number": "83", "ReferenceId": "24332040", "FullCitation": "Chen X, et al. Cancer Cell (2013) pmid: 24332040", "Include": "true"}, {"number": "84", "ReferenceId": "30889380", "FullCitation": "Steele CD, et al. Cancer Cell (2019) pmid: 30889380", "Include": "true"}, {"number": "85", "ReferenceId": "31699828", "FullCitation": "Casey DL, et al. Clin Cancer Res (2020) pmid: 31699828", "Include": "true"}, {"number": "86", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "87", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "88", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "89", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "90", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "91", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "92", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "93", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "94", "ReferenceId": "30557521", "FullCitation": "Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521", "Include": "true"}, {"number": "95", "ReferenceId": "35101941", "FullCitation": "Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941", "Include": "true"}, {"number": "96", "ReferenceId": "34876409", "FullCitation": "Friedman CF, et al. Cancer Discov (2022) pmid: 34876409", "Include": "true"}, {"number": "97", "ReferenceId": "35274716", "FullCitation": "Sturgill EG, et al. Oncologist (2022) pmid: 35274716", "Include": "true"}, {"number": "98", "ReferenceId": "32010646", "FullCitation": "AlAzab RS, et al. Res Rep Urol (2019) pmid: 32010646", "Include": "true"}, {"number": "99", "ReferenceId": "26279736", "FullCitation": "Citak EC, et al. Can Urol Assoc J () pmid: 26279736", "Include": "true"}, {"number": "100", "ReferenceId": "30545225", "FullCitation": "Hu\u013eov\u00e1 S, et al. Klin Onkol (2018) pmid: 30545225", "Include": "true"}, {"number": "101", "ReferenceId": "19636271", "FullCitation": "Vistica DT, et al. J. Pediatr. Hematol. Oncol. (2009) pmid: 19636271", "Include": "true"}, {"number": "102", "ReferenceId": "23226201", "FullCitation": "Covell DG, et al. PLoS ONE (2012) pmid: 23226201", "Include": "true"}, {"number": "103", "ReferenceId": "22419845", "FullCitation": "Ford KM, et al. Mol. Vis. (2012) pmid: 22419845", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2023_04_26 18:46:19", "OpName": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Lena Stuart, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "668x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "0 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "SOFT TISSUE", "disease_ontology": "Soft tissue perivascular epithelioid cell tumor (PEComa)", "flowcell_analysis": "2000028785", "gender": "female", "pathology_diagnosis": "PEcoma", "percent_tumor_nuclei": "40", "pipeline_version": "v3.21.1", "purity_assessment": "40.6", "specimen": "ORD_1611555_01*US1538289.01", "study": "CLINICAL_HEME_COMPLETE", "test_request": "ORD_1611555_01", "test_type": "HemeComplete", "tissue_of_origin": "Vagina", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": [{"bait_set": "R2", "mean_exon_depth": "512.07", "name": "SQ_US1538289.01_1", "nucleic_acid_type": "RNA"}, {"bait_set": "D2", "mean_exon_depth": "683.75", "name": "SQ_US1538289.01_2", "nucleic_acid_type": "DNA"}]}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.4692", "cds_effect": "4891A>C", "depth": "699", "equivocal": "false", "functional_effect": "missense", "gene": "NUP98", "percent_reads": "46.92", "position": "chr11:3704457", "protein_effect": "K1631Q", "status": "unknown", "strand": "_", "transcript": "NM_016320", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.3516", "cds_effect": "2434C>T", "depth": "401", "equivocal": "false", "functional_effect": "missense", "gene": "FLT1", "percent_reads": "35.16", "position": "chr13:28913359", "protein_effect": "R812W", "status": "unknown", "strand": "_", "transcript": "NM_002019", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.5182", "cds_effect": "3374T>C", "depth": "604", "equivocal": "false", "functional_effect": "missense", "gene": "APC", "percent_reads": "51.82", "position": "chr5:112174665", "protein_effect": "V1125A", "status": "unknown", "strand": "+", "transcript": "NM_000038", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.4903", "cds_effect": "342T>G", "depth": "773", "equivocal": "false", "functional_effect": "missense", "gene": "ASXL1", "percent_reads": "49.03", "position": "chr20:31016020", "protein_effect": "N114K", "status": "unknown", "strand": "+", "transcript": "NM_015338", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.5139", "cds_effect": "44C>T", "depth": "360", "equivocal": "false", "functional_effect": "missense", "gene": "SOCS1", "percent_reads": "51.39", "position": "chr16:11349292", "protein_effect": "T15I", "status": "unknown", "strand": "_", "transcript": "NM_003745", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.4716", "cds_effect": "295C>T", "depth": "545", "equivocal": "false", "functional_effect": "missense", "gene": "MAP3K14", "percent_reads": "47.16", "position": "chr17:43366633", "protein_effect": "R99C", "status": "unknown", "strand": "_", "transcript": "NM_003954", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}, {"allele_fraction": "0.4551", "cds_effect": "9844C>A", "depth": "523", "equivocal": "false", "functional_effect": "missense", "gene": "PRKDC", "percent_reads": "45.51", "position": "chr8:48715945", "protein_effect": "R3282S", "status": "unknown", "strand": "_", "transcript": "NM_006904", "dna_evidence": {"sample": "SQ_US1538289.01_2"}}]}, "copy_number_alterations": null, "rearrangements": {"rearrangement": {"description": "fusion", "equivocal": "false", "in_frame": "Yes", "other_gene": "NONO", "pos1": "chrX:48895549_48895589", "pos2": "chrX:70518566_70518606", "status": "known", "supporting_read_pairs": "769", "targeted_gene": "TFE3", "type": "fusion", "rna_evidence": {"sample": "SQ_US1538289.01_1"}}}, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "0.0", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}